FDA Toughens Stance on Global Clinical Trial Data
The agency plans more foreign inspections and greater transparency on data-access issues, urging sponsors to bake inspectability into their regulatory strategy from the start.
The US Food and Drug Administration has signaled it will intensify its scrutiny of clinical trial data from outside the United States. In a recent policy statement, agency leaders from the drug, biologics, and device centers committed to increasing foreign bioresearch monitoring (BIMO) inspections, including for early-stage Phase 1 trials, and refining risk-based criteria for site selection. The FDA also plans to increase transparency by publishing more information about inspection findings and any barriers encountered, such as sites denying or conditioning access.
Life sciences and medtech sponsors who rely on ex-US trials to control costs and access patient populations face heightened regulatory risk. Data from sites that fail to meet Good Clinical Practice (GCP) standards or that cannot be inspected by the agency may be rejected, potentially delaying or derailing marketing applications for critical assets. This development, viewed alongside geopolitical tensions like the BIOSECURE Act, requires sponsors to integrate site inspectability and data provenance into their core regulatory strategy, treating potential access issues as a material risk factor from the outset.